

## ASX Release

### ENTITLEMENT OFFER : DESPATCH OF OFFER BOOKLET AND ENTITLEMENT AND ACCEPTANCE FORM

Brisbane, Australia 8 August 2019: Oventus Medical Ltd ("Oventus" or "Company") (ASX: OVN), is pleased to announce that the Entitlement Offer Booklet and accompanying personalised Entitlement & Acceptance Form relating to its pro-rata non renounceable shareholder entitlement offer (**Offer**) announced on Friday, 26 July 2019, was despatched to eligible shareholders today.

#### Key Dates

As a reminder, the key dates are as follows:

Indicative Timetable for the Entitlement Offer and two tranche Placement	
Activity	Date
Offer Booklet and Entitlement and Acceptance Form sent to Eligible Shareholders	Thursday, 8 August 2019
Offer opens	Thursday, 8 August 2019
Despatch Notice of Meeting to approve the issue of the Tranche 2 Placement Shares	Thursday, 8 August 2019
Last day to extend the Closing Date	Friday, 16 August 2019
Closing Date for acceptances under the Entitlement Offer (5.00pm Melbourne time)	Wednesday, 21 August 2019
Quotation on deferred settlement basis	Thursday, 22 August 2019
ASX notified of shortfall	Friday 23 August 2019
Allotment of New Shares issued under the Entitlement Offer and lodgement of Appendix 3B and 708A cleansing notice (for the underwritten shortfall)	Wednesday, 28 August 2019
Expected despatch of Holding Statement and normal ASX trading for New Shares issued under the Entitlement Offer	Thursday, 29 August 2019
General meeting to approve the issue of the Tranche 2 Placement Shares	Monday, 9 September 2019

**Indicative Timetable for the Entitlement Offer and two tranche Placement**

Activity	Date
Issue of the Tranche 2 Placement Shares under the Tranche 2 Placement	Tuesday, 17 September 2019

The above timetable is subject to change and Oventus reserves the right to withdraw or vary the timetable for the Offer without notice. In particular, Oventus reserves the right to extend the Closing Date for the Entitlement Offer, to accept late applications whether generally or in particular cases or to withdraw the Entitlement Offer without prior notice.

**About Oventus – see more at [www.o2vent.com](http://www.o2vent.com)**

Oventus is a Brisbane based medical device company that is commercialising a unique treatment platform for sleep apnoea and snoring. The Company has a collaborative Sleep Physician/ Dental strategy that streamlines patients' access to treatment. The Oventus lab model incorporates digital technology via intra oral scanning to achieve operational efficiencies, accuracy and ultimately patient outcomes.

Unlike other oral appliances or CPAP interfaces, Oventus O2Vent® devices manage the entire upper airway via a unique and patented built-in airway. O2Vent® devices allow for airflow to the back of the mouth while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue. The devices reduce airway collapsibility and manage mouth breathing while keeping the airway stable.

O2Vent® devices are particularly designed for the many people that have nasal obstruction. They allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

The ExVent™ is a valve accessory that fits into the open airway of the O2Vent® Optima device, to augment traditional oral appliance therapy by stabilising the airway. The ExVent™ valve contains air vents that open fully on inhalation for unobstructed airflow. The valve closes on exhalation, directing the air through the vents, creating the mild resistance or airway support required to keep the airway stable (known as PEEP, positive end expiratory pressure).

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.<sup>1</sup>

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP<sup>2</sup>. Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment<sup>3</sup>. The O2Vent® Optima and ExVent™ provide a discreet and comfortable alternative to CPAP for the treatment of OSA.

<sup>1</sup> Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.

<sup>2</sup> Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003

<sup>3</sup> Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.